on each IFAC so that a broad range of industry perspectives are represented.

Committees meet an average of four times a year in Washington, D.C. Members are responsible for all travel expenses incurred to attend the meetings.

**Membership**

ISAC and IFAC members are appointed jointly by the Secretary of Commerce and the USTR. Appointments are made at the rechartering of each committee and periodically throughout the two-year charter period. Members serve at the discretion of the Secretary and USTR. Appointments to an ISAC/IFAC expire at the end of the committee's charter. However, members may be reappointed for one or more additional terms should the committee's charter be renewed and if the member proves to work effectively with the committee and his/her expertise is still needed.

Each committee is made up of approximately 30–50 members, based on the Committee charter. Each committee selects a chairperson from the membership of the committee.

**Qualifications**

For all committees, the Secretary and USTR invite nominations of U.S. citizens who are executives and managers of U.S. manufacturing or service companies that trade internationally. The Secretary and USTR also invite nominations of executives representing trade associations whose members are U.S. companies that trade internationally. Companies must be at least 51 percent beneficially-owned by U.S. persons. U.S.-based subsidiaries of foreign companies do not qualify for representation on the committees.

Nominees are considered based upon their ability to carry out the goals of section 135 of the Trade Act of 1974, as amended. Secondary criteria are ensuring that the committee is balanced in terms of points of view, demographies, geography and company size.

**Application Procedures**

Requests for applications should be sent to the Director of the Industry Consultations Program, U.S. Department of Commerce, 14th and Constitution Avenue, NW, Room 2015–B, Washington, D.C. 20230.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C., app. 2) and 21 CFR part 14 relating to advisory committees.

Dated: February 23, 1999.

**Michael J. Copps,**

*Assistant Secretary for Trade Development.*

[FR Doc. 99–5305 Filed 3–3–99; 8:45 am]

BILLING CODE 3510–DR–U

## DEPARTMENT OF COMMERCE

### National Institute of Standards and Technology

### Announcement of a Public Workshop Regarding Conformity Assessment Bodies for the Medicare Devices Annex of the US/EC Mutual Recognition Agreement

**AGENCY:** National Institute of Standards and Technology, DOC.

**ACTION:** Notice of public meeting.

**SUMMARY:** The National Institute of Standards and Technology, (NIST) invites interested parties to attend a half-day workdshop for the development of requirements for a sub-program under the National Voluntary Conformity Assessment System Evaluation (NVCASE) Program. The sub-program will satisfy the product testing and quality system registration requirements of the Medical Devices Annex of the United States/European Commission Mutual Recognition Agreement. NVCASE procedures require NIST to consult the public establishing requirements to be applied in evaluations conducted within the scope of NVCASE programs. NIST, Food and Drug Administration (FDA), and European Commission (EC) personnel will participate in this workshop. There is no fee for the workshop; however, all attendees must register in advance with the Conformity Assessment Body Response Manager no later than April 2, 1999.

**DATES:** The NVCASE workshop will be held on April 15, 1999, from 9:00 a.m. to 12:00 p.m.

**ADDRESSES:** The workshop will be held at the National Institute of Standards and Technology in the Red Auditorium, Administration Building, located at 100 Bureau Drive, Gaithersburg, MD 20899.

**FOR FURTHER INFORMATION CONTACT:** For further information, you may telephone 301–975–5120. You may register for the workshop by E-mail at scp@nist.gov or by fax at 301–975–5414. You may also register by U.S. mail addressed to Conformity Assessment Body Response Manager, NIST, 100 Bureau Drive, Stop 2100, Gaithersburg, MD 20899–2100.

**SUPPLEMENTARY INFORMATION:** In accordance with Title 15 Part 286.2(b) of the Code of Federal Regulations, NIST has established this program pursuant to a written request from a U.S. Government Agency, the Food and Drug Administration, in a letter dated March 1, 1998. The FDA announced their intend to use NIST NVCASE program for the Medical Devices Annex of the US/EC Mutual Recognition Agreement in the **Federal Register** on July 2, 1998 (63 FR 36247–36248.

The NVCASE regulations found at 15 CFR Part 286 require NIST to consult the public when establishing requirements to be applied in evaluations conducted within the scope of NVCASE programs. This program under NVCASE will allow U.S. bodies to satisfy the conformity assessment requirements of the Medical Devices Annex of the US/EC Mutual Recognition Agreement.

The NVCASE public workshop will follow the European Commission training workshop for Conformity Assessment Bodies in which EC personnel will outline the requirements of the Medical Devices Annex of the MRA. NIST, FDA and EC personnel will participate in this public workshop. Both NVCASE and EC training workshops will be held at the same location. The text of the US/EC MRA for the Medical Devices sectoral annex can be accessed on the Internet at http://www.iep.doc.gov/mra/mra.htm.

Dated: February 25, 1999.

**Karen H. Brown,**

*Deputy Director.*

[FR Doc. 99–5385 Filed 3–3–99; 8:45 am]

BILLING CODE 3510–13–M

## DEPARTMENT OF COMMERCE

### Patent and Trademark Office

### Grant of Certificate of Interim Extension of the Term of U.S. Patent No. 4,229,449: Roboxetine Mesylate

**AGENCY:** Patent and Trademark Office, Commerce.

**ACTION:** Notice of interim patent term extension.

**SUMMARY:** The Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,229,449.

**FOR INFORMATION CONTACT:** Karin Tyson by telephone at (703) 305–9285; by mail marked to her attention and addressed to the Assistant Commissioner for Patents, Box DAC, Washington, DC 20231; by fax marked to her attention at (703) 308–6916, or by e-mail to karin.tyson@uspto.gov.

**SUPPLEMENTARY INFORMATION:** Section 156 of Title 35, United States Code,

generally provides that the term of a patent may be extended for a period of up to 5 years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. Under Section 156(e)(1), a patent is eligible for term extension only if regulatory review of the claimed product was completed before the original patent term expired.

On December 3, 1993, § 156 was amended by Pub. L. No. 103–179 to provide that if the owner of record of the patent or its agent reasonably expects the applicable regulatory review period to extend beyond the expiration of the patent, the owner or its agent may submit an application to the Commissioner of Patents and Trademarks for an interim extension of the patent term. If the Commissioner determines that, except for permission to market or use the product commercially, the patent would be eligible for a statutory extension of the patent term, the Commissioner shall issue to the applicant a certificate of interim extension for a period of not more that one year.

On October 9, 1998, patent owner Pharmacia & Upjohn, S.p.A., filed an application under 35 U.S.C. 156(d)(5) for interim extension of the term of U.S. Patent No. 4,229,449. The patent claims the active ingredient roboxetine mesylate. The application indicates that a New Drug Application for the human drug product roboxetine mesylate has been filed and is currently undergoing a regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Since it is apparent that the regulatory review period will extend beyond the date of expiration of the patent, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. Accordingly, an interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,229,449 is granted for a period of one year from the original expiration date of the patent, January 8, 1999.

Dated: February 22, 1999.

**Q. Todd Dickinson,**

*Acting Assistant Secretary of Commerce and Acting Commissioner of Patents and Trademarks.*

[FR Doc. 99–5291 Filed 3–3–99; 8:45 am]

**BILLING CODE 3510–16–P**

## COMMODITY FUTURES TRADING COMMISSION

### Applications of the Chicago Mercantile Exchange for Designation as a Contract Market in E-Mini Nasdaq 100 Futures and Options

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Notice of availability of terms and conditions of proposed commodity futures and options contract.

**SUMMARY:** The Chicago Mercantile Exchange (CME or Exchange) has applied for designation as a contract market in E-Mini Nasdaq 100 futures and options. The Acting Director of the Division of Economic Analysis (Division) of the Commission, acting pursuant to the authority delegated by Commission Regulation 140.96, has determined that publication of the proposals for comment is in the public interest, will assist the Commission in considering the views of interested persons, and is consistent with the purpose of the Commodity Exchange Act.

**DATES:** Comments must be received on or before March 19, 1999.

**ADDRESSES:** Interested persons should submit their views and comments to Jean A. Webb, Secretary, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW., Washington, DC 20581. In addition, comments may be sent by facsimile transmission to facsimile number (202) 418–5521 or by electronic mail to *secretary@cftc.gov*. Reference should be made to the CME E-Mini Nasdaq 100 futures and option contracts.

**FOR FURTHER INFORMATION CONTACT:** Please contact Thomas Leahy of the Division of Economic Analysis, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC (202) 418–5278. Facsimile number: (202) 418–5527. Electronic mail: *tleahy@cftc.gov*.

**SUPPLEMENTARY INFORMATION:** There are no substantive issues raised by the applications. In this regard, the proposed contracts are substantially identical (except for the contract size and the minimum price fluctuation) to previously approved contracts based on the Nasdaq 100 index. In approving the existing Nasdaq 100 index contracts, the Commission determined that those contracts satisfied the requirements of the Accord. Accordingly, the Division believes that an abbreviated 15-day comment period is appropriate for the subject applications.

Copies of the terms and conditions will be available for inspection at the Office of the Secretariat, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC 20581. Copies of the terms and conditions can be obtained through the Office of the Secretariat by mail at the above address or by phone at (202) 418–5100.

Other materials submitted by the CME in support of the applications for contract market designation may be available upon request pursuant to the Freedom of Information Act (5 U.S.C. 552) and the Commission's regulations thereunder (17 CFR Part 145 (1997)), except to the extent they are entitled to confidential treatment as set forth in 17 CFR 145.5 and 145.9. Requests for copies of such materials should be made to the FOI, Privacy and Sunshine Act Compliance Staff of the Office of Secretariat at the Commission's headquarters in accordance with 17 CFR 145.7 and 145.8.

Any person interested in submitting written data, views, or arguments on the proposed terms and conditions, or with respect to other material submitted by the CME, should send such comments to Jean A. Webb, Secretary, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC 20581 by the specified date.

Issued in Washington, DC, on February 25, 1999.

**John R. Mielke,**

*Acting Director.*

[FR Doc. 99–5366 Filed 3–3–99; 8:45 am]

**BILLING CODE 6351–01–M**

## COMMODITY FUTURES TRADING COMMISSION

### Chicago Board of Trade Petition for Exemption From the Dual Trading Prohibition in the U.S. Treasury Bond Futures Contract Traded on the Project A Electronic Trading System

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Order.

**SUMMARY:** The Commodity Futures Trading Commission (''Commission'') is granting the petition of the Chicago Board of Trade (''CBT'' or ''Exchange'') for exemption from the prohibition against dual trading in the U.S. Treasury Bond futures contract traded on its Project A electronic trading system.

**DATES:** This Order is to be effective February 26, 1999.

**FOR FURTHER INFORMATION CONTACT:** Andrew S. Baer, Attorney-Advisor,